New Drug Application News and Research

RSS
Two-drug combination improves lung function in some cystic fibrosis patients

Two-drug combination improves lung function in some cystic fibrosis patients

Egalet announces business highlights, financial results for first quarter 2015

Egalet announces business highlights, financial results for first quarter 2015

Symbiomix closes $41 million Series A financing and reports positive results from SYM-1219 Phase 2 trial

Symbiomix closes $41 million Series A financing and reports positive results from SYM-1219 Phase 2 trial

Juniper's total revenues increase 19% to $8.3 million in first quarter 2015

Juniper's total revenues increase 19% to $8.3 million in first quarter 2015

Mylan releases generic version of Seasonale Tablets in the U.S.

Mylan releases generic version of Seasonale Tablets in the U.S.

Indivior reports top-line results from RBP-7000 phase 3 trial for treatment of schizophrenia

Indivior reports top-line results from RBP-7000 phase 3 trial for treatment of schizophrenia

FDA grants tentative approval to Amerigen's ANDA for generic version of Toviaz

FDA grants tentative approval to Amerigen's ANDA for generic version of Toviaz

Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine reports net loss of $1.2 million for first quarter 2015

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

TWi signs Settlement Agreement with Takeda on patent litigation related to generic Dexilant

TWi signs Settlement Agreement with Takeda on patent litigation related to generic Dexilant

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

Boehringer Ingelheim seeks FDA approval for Pradaxa to treat DVT and PE

Boehringer Ingelheim seeks FDA approval for Pradaxa to treat DVT and PE

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Japanese MHLW grants priority review for AbbVie's investigational hepatitis C treatment

Japanese MHLW grants priority review for AbbVie's investigational hepatitis C treatment

Aeterna Zentaris plans to conduct Macrilen Phase 3 clinical study for AGHD

Aeterna Zentaris plans to conduct Macrilen Phase 3 clinical study for AGHD

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

AstraZeneca selects Regulus' RG-125 as clinical candidate for treatment of NASH

AstraZeneca selects Regulus' RG-125 as clinical candidate for treatment of NASH

Mylan announces the U.S. launch of first generic version of Generess Fe tablets

Mylan announces the U.S. launch of first generic version of Generess Fe tablets